Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UAECell19 in healthy volunteers (SANTANA)
NCT04645485Phase 1Completed
- Sponsor
- Abu Dhabi Stem Cells Center
- Start
- May 2020
- Primary completion
- Jun 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of UAECell19 in coronavirus disease 2019 (COVID-19), sponsored by Abu Dhabi Stem Cells Center. Primary endpoints: Adverse Reactions incidence at 28 days, St. George's Respiratory Questionnaire at 28 days and 1 more. Started May 2020; status: completed.
02
Drugs
UAECell19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04645485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04645485.